BC Week In Review | Oct 17, 2011
Clinical News

OPS101 regulatory update

EMA granted Orphan Drug designation for OctreoPharm's OPS101 to diagnose gastro-entero-pancreatic neuroendocrine tumors. The gallium-68-labeled radioactive agent for PET imaging is in Phase I testing. OctreoPharm Sciences GmbH , Berlin, Germany   Novartis AG (NYSE:NVS; SIX:NOVN),...
BC Week In Review | Oct 17, 2011
Company News

OctreoPharm, Novartis deal

OctreoPharm exercised an option under a 2009 deal with Novartis to license exclusive, worldwide rights to develop and commercialize OPS101 . The option was triggered after OctreoPharm's provided the pharma with "proof of financial standing" to...
Items per page:
1 - 2 of 2